Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott Joins Race To Develop Nerve Growth Factor Antibody With PanGenetics Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Abbott will pay PanGenetics $170 million upfront for the Phase I antibody. Pfizer, Johnson & Johnson and Sanofi-Aventis are among the firms with NGF antibodies in development.

You may also be interested in...

Deals Of The Week: Sandoz/Fougera, Abbott/Action Pharma/Zealand, AstraZeneca/Axerion

New company Tolero helps MannKind de-risk a preclinical BTK inhibitor program in a “double-jointed” deal in which the “bio-bucks” eventually could flow in either direction.

Anti-Nerve Growth Factor Developers Face Go/No-Go Recommendation From Advisory Panel

FDA sets March 12 as date for the Arthritis Advisory Committee to weigh in on whether safety issues are a barrier to development of anti-NGF compounds as analgesics. Developers’ trials are on hold while FDA considers the potential for adverse effects seen in osteoarthritis patients taking the monoclonal antibodies for pain.

Creabilis Pulls In Corporate VC With €15M Series B

Abbott Biotech Ventures is the lead investor in a Series B fundraising for Creabilis to move its psoriasis candidate through Phase II.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts